{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:14:23Z","timestamp":1792012463963,"version":"4.4.0"},"reference-count":176,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T00:00:00Z","timestamp":1605744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"DOI":"10.3389\/fpsyt.2020.548505","type":"journal-article","created":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T04:46:23Z","timestamp":1605761183000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":80,"title":["Glutamate Systems in DSM-5 Anxiety Disorders: Their Role and a Review of Glutamate and GABA Psychopharmacology"],"prefix":"10.3389","volume":"11","author":[{"given":"Madeeha","family":"Nasir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Trujillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer B.","family":"Dwyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary W.","family":"Rupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Bloch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,11,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1001\/archpsyc.62.6.617","article-title":"Prevalence, severity, and comorbidity of 12-month dSM-IV disorders in the national comorbidity survey replication","volume":"62","author":"Kessler","year":"2005","journal-title":"Arch Gen Psychiatry."},{"key":"B2","doi-asserted-by":"publisher","year":"2013","journal-title":"DSM 5","DOI":"10.1176\/appi.books.9780890425596.744053"},{"key":"B3","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/da.20674","article-title":"The relationship between anxiety disorders and suicide attempts: findings from the national epidemiologic survey on alcohol and related conditions","volume":"27","author":"Nepon","year":"2010","journal-title":"Depress Anxiety."},{"key":"B4","first-page":"6","article-title":"The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders","volume":"24","author":"Schaffer","year":"2012","journal-title":"Ann Clin Psychiatry"},{"key":"B5","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/da.10131","article-title":"Medical and productivity costs of anxiety disorders: case control study","volume":"19","author":"Marciniak","year":"2004","journal-title":"Depress Anxiety."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1002\/da.20624","article-title":"Severity of anxiety and work-related outcomes of patients with anxiety disorders","volume":"26","author":"Erickson","year":"2009","journal-title":"Depress Anxiety."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1097\/00004583-199309000-00044","article-title":"Practice parameters for the assessment and treatment of anxiety disorders","volume":"32","author":"Bernstein","year":"1993","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"key":"B8","volume-title":"Tuberculosis: Clinical Diagnosis and Management of Tuberculosis, and Measures for its Prevention and Control","year":"2006"},{"key":"B9","unstructured":"SteinMB\n            Marcia GoinCK\n            PollackMH\n            Roy-ByrneP\n            SareenJ\n            SimonNM\n          18340692Practice Guideline For The Treatment Of Patients With Panic Disorder Second Edition Work Group On Panic Disorder Steering Committee On Practice Guidelines2010"},{"key":"B10","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/YIC.0000000000000078","article-title":"Efficacy of treatments for anxiety disorders: a meta-analysis","volume":"30","author":"Bandelow","year":"2015","journal-title":"Int Clin Psychopharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1080\/15374416.2017.1371028","article-title":"Monotherapy insufficient in severe anxiety? Predictors and moderators in the child\/adolescent anxiety multimodal study","volume":"47","author":"Taylor","year":"2018","journal-title":"J Clin Child Adolesc Psychol."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpr.2015.08.004","article-title":"Response rates for cBT for anxiety disorders: need for standardized criteria","author":"Loerinc","year":"2015","journal-title":"Clinical Psychology Review. Elsevier Inc"},{"key":"B13","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1176\/appi.ps.201400134","article-title":"Barriers to and facilitators in the implementation of cognitive-behavioral therapy for youth anxiety in the community","volume":"66","author":"Ringle","year":"2015","journal-title":"Psychiatric Services."},{"key":"B14","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/da.22854","article-title":"Systematic review and meta-analysis: dose-response curve of sSRIs and sNRIs in anxiety disorders","volume":"36","author":"Jakubovski","year":"2019","journal-title":"Depress Anxiety."},{"key":"B15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14740338.2018.1429403","article-title":"Risks and benefits of medications for panic disorder: a comparison of sSRIs and benzodiazepines","volume":"17","author":"Quagliato","year":"2018","journal-title":"Expert Opinion on Drug Safety."},{"key":"B16","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.pbb.2013.11.003","article-title":"Antidepressant-induced sexual dysfunction in men","volume":"121","author":"Segraves","year":"2014","journal-title":"Pharm Biochem Behav."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/j.mayocp.2016.04.033","article-title":"Antidepressant-Induced female sexual dysfunction","volume":"91","author":"Lorenz","year":"2016","journal-title":"Mayo Clinic Proc."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1517\/14740338.2014.951324","article-title":"Sexual dysfunction associated with major depressive disorder and antidepressant treatment","volume":"13","author":"Clayton","year":"2014","journal-title":"Expert Opin Drug Safety."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.4088\/JCP.14r09699","article-title":"Summary of findings from the fDA regulatory science forum on measuring sexual dysfunction in depression trials","volume":"76","author":"Kronstein","year":"2015","journal-title":"J Clin Psychiatry."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0165-1781(01)00265-7","article-title":"Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients","volume":"103","author":"Asnis","year":"2001","journal-title":"Psychiatry Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1176\/ajp.155.1.36","article-title":"Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder","volume":"155","author":"Ballenger","year":"1998","journal-title":"Am J Psychiatry."},{"key":"B22","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1192\/bjp.173.1.54","article-title":"Sertraline in the treatment of panic disorder. A multi-site, double- blind, placebo-controlled, fixed-dose investigation","volume":"173","author":"Londborg","year":"1998","journal-title":"Br J Psychiatry."},{"key":"B23","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1192\/bjp.179.6.514","article-title":"Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder. Randomised, placebo-controlled trial","volume":"179","author":"Michelson","year":"2001","journal-title":"Br J Psychiatry."},{"key":"B24","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1517\/14728214.2015.1049996","article-title":"Emerging drugs for the treatment of anxiety","volume":"20","author":"Murrough","year":"2015","journal-title":"Exp Opin Emerg Drugs."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1176\/ajp.155.9.1189","article-title":"Sertraline in the treatment of panic disorder: a double-blind multicenter trial","volume":"155","author":"Pohl","year":"1998","journal-title":"Am J Psychiatry."},{"key":"B26","first-page":"255","article-title":"Selective serotonin reuptake inhibitor discontinuation1 syndrome: proposed diagnostic criteria","volume":"25","author":"Black","year":"2000","journal-title":"J Psychiatry Neurosci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2174\/1389450111314030007","article-title":"Clonazepam for the treatment of panic disorder","volume":"14","author":"Nardi","year":"2013","journal-title":"Current Drug Targets."},{"key":"B28","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.psychres.2005.05.011","article-title":"A three-year follow-up study of patients with the respiratory subtype of panic disorder after treatment with clonazepam","volume":"137","author":"Nardi","year":"2005","journal-title":"Psychiatry Res"},{"key":"B29","first-page":"4","article-title":"Attitudes toward benzodiazepines over the years","volume":"66","author":"Rosenbaum","year":"2005","journal-title":"J Clin Psychiatry."},{"key":"B30","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2174\/1568007024606258","article-title":"N-methyl-D-aspartate receptor-coupled glycineB receptors in the pathogenesis and treatment of schizophrenia: a critical review","volume":"1","author":"Millan","year":"2002","journal-title":"Curr Drug Targets. CNS Neurol Disord"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1111\/j.1471-4159.1993.tb13387.x","article-title":"Stress preferentially increases extraneuronal levels of excitatory amino acids in the prefrontal cortex: comparison to hippocampus and basal ganglia","volume":"60","author":"Moghaddam","year":"1993","journal-title":"J Neurochem."},{"key":"B32","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1023\/a:1007062109386","article-title":"Gene expression of two glutamate receptor subunits in response to repeated stress exposure in rat hippocampus","volume":"20","author":"Schwendt","year":"2000","journal-title":"Cell Mol Neurobiol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2165\/11533230-000000000-00000","article-title":"Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists","volume":"24","author":"Krystal","year":"2010","journal-title":"CNS Drugs"},{"key":"B34","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.pharmthera.2007.04.007","article-title":"Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs","volume":"115","author":"Palucha","year":"2007","journal-title":"Pharmacol Ther."},{"key":"B35","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.neuint.2009.02.019","article-title":"Metabotropic glutamate receptors in the tripartite synapse as a target for new psychotropic drugs","volume":"55","author":"Wiero\u0144ska","year":"2009","journal-title":"Neurochem Int"},{"key":"B36","doi-asserted-by":"crossref","DOI":"10.1093\/acprof:oso\/9780195159561.001.1","volume-title":"The Synaptic Organization of the Brain","author":"Shepherd","year":"2004"},{"key":"B37","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejphar.2009.10.014","article-title":"Hippocampal NMDA receptors and anxiety: At the interface between cognition and emotion","volume":"626","author":"Barkus","year":"2010","journal-title":"Eur J Pharm"},{"key":"B38","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s00213-005-2200-z","article-title":"Ionotropic and metabotropic glutamate receptor structure and pharmacology","volume":"179","author":"Kew","year":"2005","journal-title":"Psychopharmacology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s11920-007-0033-7","article-title":"Glutamate and anxiety disorders","volume":"9","author":"Amiel","year":"2007","journal-title":"Curr Psychiatry Rep"},{"key":"B40","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1523\/jneurosci.21-22-j0001.2001","article-title":"The existence of a second vesicular glutamate transporter specifies subpopulations of glutamatergic neurons","volume":"21","author":"Herzog","year":"2001","journal-title":"J Neurosci."},{"key":"B41","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrd1630","article-title":"Metabotropic glutamate receptors as novel targets for anxiety and stress disorders","volume":"4","author":"Swanson","year":"2005","journal-title":"Nat Rev Drug Dis"},{"key":"B42","first-page":"7","article-title":"The glutamate receptor ion channels","volume":"51","author":"Dingledine","year":"1999","journal-title":"Pharmacol Rev."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/S0092-8674(00)81827-9","article-title":"The essential role of hippocampal cA1 nMDA receptor-dependent synaptic plasticity in spatial memory","volume":"87","author":"Tsien","year":"1996","journal-title":"Cell."},{"key":"B44","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1124\/pr.109.002451","article-title":"Glutamate receptor ion channels: structure, regulation, and function","volume":"62","author":"Traynelis","year":"2010","journal-title":"Pharm Rev."},{"key":"B45","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.neuron.2005.01.031","article-title":"Crystal structures of the gluR5 and gluR6 ligand binding cores: molecular mechanisms underlying kainate receptor selectivity","volume":"45","author":"Mayer","year":"2005","journal-title":"Neuron."},{"key":"B46","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nrn2911","article-title":"Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders","volume":"11","author":"Hardingham","year":"2010","journal-title":"Nat Rev Neurosci"},{"key":"B47","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/npp.2016.199","article-title":"Inflammation, glutamate, and glia: a Trio of trouble in mood disorders","volume":"42","author":"Haroon","year":"2017","journal-title":"Neuropsychopharmacology."},{"key":"B48","first-page":"19","article-title":"Magnetic resonance spectroscopy in social phobia: preliminary findings","volume":"54","author":"Davidson","year":"1993","journal-title":"J Clin Psychiatry"},{"key":"B49","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1176\/appi.ajp.157.7.1175","article-title":"N-Acetylaspartate concentration in the anterior cingulate of maltreated children and adolescents with pTSD","volume":"157","author":"De Bellis","year":"2000","journal-title":"Am J Psychiatry."},{"key":"B50","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/mrm.1910400110","article-title":"In vivo proton magnetic resonance spectroscopy of the medial temporal lobes of subjects with combat-related posttraumatic stress disorder","volume":"40","author":"Freeman","year":"1998","journal-title":"Magn Reson Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1176\/appi.ajp.161.6.1119","article-title":"Dorsolateral prefrontal cortical pathology in generalized anxiety disorder: a proton magnetic resonance spectroscopic imaging study","volume":"161","author":"Mathew","year":"2004","journal-title":"Am J Psychiatry."},{"key":"B52","volume-title":"N-Acetylaspartate in the cNS: From Neurodiagnostics to Neurobiology. Progress in Neurobiology","author":"Moffett","year":"2007"},{"key":"B53","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.pscychresns.2005.12.006","article-title":"A magnetic resonance spectroscopy investigation of obsessive-compulsive disorder and anxiety","volume":"146","author":"Whiteside","year":"2006","journal-title":"Psychiatry Res."},{"key":"B54","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.pscychresns.2010.10.008","article-title":"Brain magnetic resonance spectroscopy in obsessive-compulsive disorder: the importance of considering subclinical symptoms of anxiety and depression","volume":"192","author":"B\u00e9dard","year":"2011","journal-title":"Psychiatry Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.pnpbp.2014.12.008","article-title":"1H-magnetic resonance spectroscopy in social anxiety disorder","volume":"58","author":"Howells","year":"2015","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/nbm.3045","article-title":"Glutamate and glutamine: a review of in vivo mRS in the human brain","author":"Ramadan","year":"2013","journal-title":"NMR Biomed"},{"key":"B57","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/1097-0193(200012)11:4<261::AID-HBM30>3.0.CO;2-6","article-title":"A. Chemical mapping of anxiety in the brain of healthy humans: an in vivo 1H-MRS study on the effects of sex, age, brain region","volume":"11","author":"Grachev","year":"2000","journal-title":"Hum Brain Mapp."},{"key":"B58","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/00001756-200502080-00024","article-title":"Anterior cingulate neurochemistry in social anxiety disorder: 1H-MRS at 4 tesla | ovid","volume":"16","author":"Phan","year":"2005","journal-title":"Neur Rep."},{"key":"B59","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.neulet.2016.11.064","article-title":"Glutamate dysregulation and glutamatergic therapeutics for PTSD: Evidence from human studies","volume":"649","author":"Averill","year":"2017","journal-title":"Neurosci Lett."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1038\/sj.npp.1300733","article-title":"Glutamatergic dysfunction in oCD","volume":"30","author":"Chakrabarty","year":"2005","journal-title":"Neuropsychopharmacology."},{"key":"B61","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/nrd2462","article-title":"Targeting the glutamatergic system to develop novel,improved therapeutics for mood disorders","volume":"7","author":"Sanacora","year":"2008","journal-title":"Nat Rev Drug Dis"},{"key":"B62","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.neuropharm.2019.05.035","article-title":"The effect of pyruvate on the development and progression of post-stroke depression: a new therapeutic approach","volume":"155","author":"Frank","year":"2019","journal-title":"Neuropharmacology."},{"key":"B63","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/tp.2012.95","article-title":"Multi-locus genome-wide association analysis supports the role of glutamatergic synaptic transmission in the etiology of major depressive disorder","volume":"2","author":"Lee","year":"2012","journal-title":"Transl Psychiatry"},{"key":"B64","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/npp.2015.266","article-title":"The genetics of stress-Related disorders: pTSD, depression, anxiety disorders","volume":"41","author":"Smoller","year":"2016","journal-title":"Neuropsychopharmacology."},{"key":"B65","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1038\/npp.2009.77","article-title":"Anti-brain autoantibodies and altered excitatory neurotransmitters in obsessive-compulsive disorder","volume":"34","author":"Bhattacharyya","year":"2009","journal-title":"Neuropsychopharmacology."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1176\/ajp.155.11.1584","article-title":"A short echo 1H spectroscopy and volumetric mRI study of the corpus striatum in patients with obsessive-compulsive disorder and comparison subjects","volume":"155","author":"Bartha","year":"1998","journal-title":"Am J Psychiatry."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1097\/00004583-200009000-00008","article-title":"Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine","volume":"39","author":"Rosenberg","year":"2000","journal-title":"J Am Acad Child Adoles Psychiatry."},{"key":"B68","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1001\/archpsyc.63.7.769","article-title":"Glutamate transporter gene sLC1A1 associated with obsessive-compulsive disorder","volume":"63","author":"Arnold","year":"2006","journal-title":"Arch Gen Psychiatry."},{"key":"B69","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1001\/archpsyc.63.7.778","article-title":"Association testing of the positional and functional candidate gene sLC1A1\/EAAC1 in early-onset obsessive-compulsive disorder","volume":"63","author":"Dickel","year":"2006","journal-title":"Arch Gen Psychiatry."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1001\/archgenpsychiatry.2009.155","article-title":"Association of the glutamate transporter gene sLC1A1 with atypical antipsychotics-induced obsessive-compulsive symptoms","volume":"66","author":"Kwon","year":"2009","journal-title":"Arch Gen Psychiatry."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1002\/ajmg.b.30713","article-title":"Evidence for potential relationship between sLC1A1 and a putative genetic linkage region on chromosome 14q to obsessive-compulsive disorder with compulsive hoarding","volume":"147","author":"Liang","year":"2008","journal-title":"Am J Med Gen."},{"key":"B72","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/ajmg.b.30914","article-title":"A family-based association study of the glutamate transporter gene sLC1A1 in obsessive-compulsive disorder in 378 families","volume":"150","author":"Shugart","year":"2009","journal-title":"Am J Med Gen."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1002\/ajmg.b.30533","article-title":"Association of the sLC1A1 glutamate transporter gene and obsessive-compulsive disorder","volume":"144","author":"Stewart","year":"2007","journal-title":"Am J Med Gen."},{"key":"B74","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/ajmg.b.31001","article-title":"A screen of sLC1A1 for oCD-related alleles","volume":"153","author":"Wang","year":"2010","journal-title":"Am J Med Gen."},{"key":"B75","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1001\/archgenpsychiatry.2009.6","article-title":"A haplotype containing quantitative trait loci for sLC1A1 gene expression and its association with obsessive-compulsive disorder","volume":"66","author":"Wendland","year":"2009","journal-title":"Arch Gen Psychiatry."},{"key":"B76","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1111\/pcn.12332","article-title":"Proton magnetic resonance spectroscopy revealed differences in the glutamate + glutamine\/creatine ratio of the anterior cingulate cortex between healthy and pediatric post-traumatic stress disorder patients diagnosed after 2008 wenchuan earthquake","volume":"69","author":"Yang","year":"2015","journal-title":"Psychiatry Clin Neurosci."},{"key":"B77","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S0924-977X(03)00100-7","article-title":"Glutamate and anxiety","volume":"14","author":"Bergink","year":"2004","journal-title":"Eur Neuropsychopharmacol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/S0006-3223(03)00528-6","article-title":"Neurobiology of antidepressant withdrawal: Implications for the longitudinal outcome of depression","volume":"54","author":"Harvey","year":"2003","journal-title":"Biol Psychiatry"},{"key":"B79","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/S0006-3223(01)01362-2","article-title":"Stress activation of glutamate neurotransmission in the prefrontal cortex: implications for dopamine-associated psychiatric disorders","volume":"51","author":"Moghaddam","year":"2002","journal-title":"Biol Psychiatry"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/nrn3138","article-title":"The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission","author":"Popoli","year":"2012","journal-title":"Nat Rev Neurosci."},{"key":"B81","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/npp.2010.88","article-title":"Glutamate receptors in extinction and extinction-based therapies for psychiatric illness","volume":"36","author":"Myers","year":"2011","journal-title":"Neuropsychopharmacol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2011.06.014","article-title":"Metabotropic and ionotropic glutamate receptors as neurobiological targets in anxiety and stress-related disorders: focus on pharmacology and preclinical translational models","author":"Harvey","year":"2012","journal-title":"Pharmacol Biochem Behav"},{"key":"B83","first-page":"165","article-title":"Evaluation of anxiolytic activity of Carum copticum by using elevated plus maze and open field method","volume":"2","author":"Kharade","year":"2011","journal-title":"Int Res J Phar."},{"key":"B84","doi-asserted-by":"publisher","first-page":"S101","DOI":"10.1590\/1516-4446-2013-1139","article-title":"Animal models of anxiety disorders and stress","volume":"35","author":"Campos","year":"2013","journal-title":"Revista Brasileira de Psiquiatria."},{"key":"B85","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1210\/endo-87-4-738","article-title":"Adrenal and urinary catecholamines in rats during adaptation to repeated immobilization stress","volume":"87","author":"Kvetnansky","year":"1970","journal-title":"Endocrinology."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0014-2999(96)00749-2","article-title":"NMDA receptors in the pontine brainstem are necessary for fear potentiation of the startle response","volume":"318","author":"Fendt","year":"1996","journal-title":"Eur J Pharmacol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1037\/0735-7044.106.3.569","article-title":"Intra-Amygdala infusion of the n-Methyl-D-Aspartate receptor antagonist aP5 blocks acquisition but not expression of fear-Potentiated startle to an auditory conditioned stimulus","volume":"106","author":"Campeau","year":"1992","journal-title":"Behav Neurosci."},{"key":"B88","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0278-5846(03)00080-0","article-title":"Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia","volume":"27","author":"Becker","year":"2003","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry."},{"key":"B89","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s11064-018-02715-y","article-title":"Effects of anesthetic ketamine on anxiety-Like behaviour in rats","volume":"44","author":"Pitsikas","year":"2019","journal-title":"Neurochem Res."},{"key":"B90","first-page":"527","article-title":"Glycine site antagonists and partial agonists inhibit n-methyl-D-aspartate receptor-mediated [3H]arachidonic acid release in cerebellar granule cells","volume":"285","author":"Viu","year":"1998","journal-title":"J Pharmacol Exp Ther."},{"key":"B91","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1037\/0735-7044.117.2.341","article-title":"Effects of d-cycloserine on extinction of conditioned freezing","volume":"117","author":"Ledgerwood","year":"2003","journal-title":"Behav Neurosci."},{"key":"B92","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1037\/0735-7044.118.3.505","article-title":"D-cycloserine and the facilitation of extinction of conditioned fear: consequences for reinstatement","volume":"118","author":"Ledgerwood","year":"2004","journal-title":"Behav Neurosci."},{"key":"B93","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.nlm.2005.01.001","article-title":"Effects of multiple exposures to d-cycloserine on extinction of conditioned fear in rats","volume":"83","author":"Parnas","year":"2005","journal-title":"Neurobiol Learn Mem."},{"key":"B94","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1523\/jneurosci.22-06-02343.2002","article-title":"Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of d-cycloserine as assessed with fear-potentiated startle in rats","volume":"22","author":"Walker","year":"2002","journal-title":"J Neurosci."},{"key":"B95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0006-8993(00)02665-2","article-title":"Expression and conditioned inhibition of fear-potentiated startle after stimulation and blockade of aMPA\/Kainate and gABA(A) receptors in the dorsal periaqueductal gray","volume":"880","author":"Fendt","year":"2000","journal-title":"Brain Res"},{"key":"B96","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00213-003-1634-4","article-title":"Topiramate attenuates exaggerated acoustic startle in an animal model of pTSD","volume":"172","author":"Khan","year":"2004","journal-title":"Psychopharmacology."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0028-3908(01)00036-3","article-title":"The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) blocks fear conditioning in rats","volume":"41","author":"Schulz","year":"2001","journal-title":"Neuropharmacology."},{"key":"B98","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s00213-005-2211-9","article-title":"The effect of the mGlu5 receptor antagonist mPEP in rodent tests of anxiety and cognition: a comparison","volume":"179","author":"Ballard","year":"2005","journal-title":"Psychopharmacology."},{"key":"B99","first-page":"651","article-title":"Anxiolytic and side-effect profile of lY354740: a potent, highly selective, orally active agonist for group iI metabotropic glutamate receptors","volume":"284","author":"Helton","year":"1998","journal-title":"J Pharmacol Exp Ther."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1037\/\/0735-7044.116.6.1075","article-title":"Group iI metabotropic glutamate receptors within the amygdala regulate fear as assessed with potentiated startle in rats","volume":"116","author":"Walker","year":"2002","journal-title":"Behav Neurosci."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/S0028-3908(99)00215-4","article-title":"LY354740, a potent group iI metabotropic glutamate receptor agonist prevents lactate-induced panic-like response in panic-prone rats","volume":"39","author":"Shekhar","year":"2000","journal-title":"Neuropharmacology."},{"key":"B102","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/sj.npp.1300321","article-title":"Anxiolytic activity of the mGLU2\/3 receptor agonist lY354740 on the elevated plus maze is associated with the suppression of stress-induced c-Fos in the hippocampus and increases in c-Fos induction in several other stress-sensitive brain regions","volume":"29","author":"Linden","year":"2004","journal-title":"Neuropsychopharmacology."},{"key":"B103","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00213-005-2146-1","article-title":"Lamotrigine has an anxiolytic-like profile in the rat conditioned emotional response test of anxiety: a potential role for sodium channels?","volume":"180","author":"Mirza","year":"2005","journal-title":"Psychopharmacology."},{"key":"B104","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1177\/0269881117705089","article-title":"Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders","volume":"31","author":"Glue","year":"2017","journal-title":"J Psychopharmacol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/npp.2017.194","article-title":"Ketamine for social anxiety disorder: a randomized, placebo-controlled crossover trial","volume":"43","author":"Taylor","year":"2018","journal-title":"Neuropsychopharmacology."},{"key":"B106","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1001\/archpsyc.63.3.298","article-title":"Augmentation of exposure therapy with d-cycloserine for social anxiety disorder","volume":"63","author":"Hofmann","year":"2006","journal-title":"Arch Gen Psychiatry."},{"key":"B107","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.biopsych.2007.11.011","article-title":"A randomized controlled trial of d-Cycloserine enhancement of exposure therapy for social anxiety disorder","volume":"63","author":"Guastella","year":"2008","journal-title":"Biol Psychiatry."},{"key":"B108","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1176\/appi.ajp.162.12.2379","article-title":"Open-label trial of riluzole in generalized anxiety disorder","volume":"162","author":"Mathew","year":"2005","journal-title":"Am J Psychiatry."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.4088\/jcp.v65n0909","article-title":"An open-label study of levetiracetam for the treatment of social anxiety disorder","volume":"65","author":"Simon","year":"2004","journal-title":"J Clin Psychiatry."},{"key":"B110","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1177\/0269881105056526","article-title":"Levetiracetam in social phobia: a placebo controlled pilot study","volume":"19","author":"Zhang","year":"2005","journal-title":"J Psychopharmacol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"627","DOI":"10.4088\/JCP.08m04949gre","article-title":"Levetiracetam in generalized social anxiety disorder: a double-blind, randomized controlled trial","volume":"71","author":"Stein","year":"2010","journal-title":"J Clin Psychiatry."},{"key":"B112","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1097\/01.jcp.0000084032.22282.ff","article-title":"A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder","volume":"23","author":"Feltner","year":"2003","journal-title":"J Clin Psychopharmacol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1176\/appi.ajp.160.3.533","article-title":"Pregabalin in generalized anxiety disorder: a placebo-controlled trial","volume":"160","author":"Pande","year":"2003","journal-title":"Am J Psychiatry."},{"key":"B114","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1001\/archpsyc.62.9.1022","article-title":"Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam","volume":"62","author":"Rickels","year":"2005","journal-title":"Arch Gen Psychiatry."},{"key":"B115","doi-asserted-by":"publisher","first-page":"771","DOI":"10.4088\/JCP.v67n0511","article-title":"Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine","volume":"67","author":"Montgomery","year":"2006","journal-title":"J Clin Psychiatry."},{"key":"B116","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/00004714-199908000-00010","article-title":"Treatment of social phobia with gabapentin: a placebo-controlled study","volume":"19","author":"Pande","year":"1999","journal-title":"J Clin Psychopharmacol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/00004714-200008000-00011","article-title":"Placebo-controlled study of gabapentin treatment of panic disorder","volume":"20","author":"Pande","year":"2000","journal-title":"J Clin Psychopharmacol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s10549-012-2251-x","article-title":"A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors","volume":"136","author":"Lavigne","year":"2012","journal-title":"Breast Cancer Res Treat."},{"key":"B119","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.4088\/JCP.v66n1109","article-title":"The selective gABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study","volume":"66","author":"Pollack","year":"2005","journal-title":"J Clin Psychiatry."},{"key":"B120","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/01.yic.0000064261.66765.9f","article-title":"Valproic acid for the treatment of social anxiety disorder","volume":"18","author":"Kinrys","year":"2003","journal-title":"Int Clin Psychopharmacol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.eurpsy.2007.08.001","article-title":"Valproate (depakine-chrono) in the acute treatment of outpatients with generalized anxiety disorder without psychiatric comorbidity: randomized, double-blind placebo-controlled study","volume":"23","author":"Aliyev","year":"2008","journal-title":"Eur Psychiatry."},{"key":"B122","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.117.015198","article-title":"Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms","volume":"70","author":"Zanos","year":"2018","journal-title":"Pharmacol Rev."},{"key":"B123","doi-asserted-by":"publisher","first-page":"5160","DOI":"10.1073\/pnas.1816071116","article-title":"Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block nMDA receptor function","volume":"116","author":"Lumsden","year":"2019","journal-title":"Proc Natl Acad Sci USA."},{"key":"B124","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41398-019-0624-1","article-title":"Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites","volume":"9","author":"Yang","year":"2019","journal-title":"Transl Psychiatry."},{"key":"B125","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol Psychiatry."},{"key":"B126","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1017\/S0033291716000064","article-title":"Single-dose infusion ketamine and non-ketamine n-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories","volume":"46","author":"Kishimoto","year":"2016","journal-title":"Psychol Med."},{"key":"B127","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1001\/jamapsychiatry.2014.62","article-title":"Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial","volume":"71","author":"Feder","year":"2014","journal-title":"JAMA Psychiatry."},{"key":"B128","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212305","volume-title":"Ketamine as Treatment for Post-Traumatic Stress Disorder: A Review. Drugs in Context","author":"Liriano","year":""},{"key":"B129","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1038\/npp.2013.150","article-title":"Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept","volume":"38","author":"Rodriguez","year":"2013","journal-title":"Neuropsychopharmacology."},{"key":"B130","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1017\/S1092852919001238","article-title":"Efficacy and safety of ketamine in the management of anxiety and anxiety spectrum disorders: a review of the literature","volume":"25","author":"Banov","year":"2019","journal-title":"CNS Spectrums"},{"key":"B131","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1177\/0269881118762073","article-title":"Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalised anxiety and social anxiety disorders","volume":"32","author":"Glue","year":"2018","journal-title":"J Psychopharmacol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2147\/ndt.s4048","article-title":"Update on the use of memantine in Alzheimer's disease","volume":"5","author":"Van Marum","year":"2009","journal-title":"Neuropsych Dis Treat"},{"key":"B133","doi-asserted-by":"publisher","first-page":"9686","DOI":"10.1523\/JNEUROSCI.1173-17.2017","article-title":"Memantine and ketamine differentially alter nMDA receptor desensitization","volume":"37","author":"Glasgow","year":"2017","journal-title":"J Neurosci."},{"key":"B134","first-page":"81","article-title":"Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: An open-label trial","volume":"42","author":"Feusner","year":"2009","journal-title":"Psychopharmacol Bull."},{"key":"B135","doi-asserted-by":"publisher","first-page":"112602","DOI":"10.1016\/j.psychres.2019.112602","article-title":"A systematic review and meta-analysis: memantine augmentation in moderate to severe obsessive-compulsive disorder","volume":"282","author":"Modarresi","year":"2019","journal-title":"Psychiatry Res"},{"key":"B136","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1002\/jps.2600620826","article-title":"GLC of cycloserine","volume":"62","author":"Sondack","year":"1973","journal-title":"J Pharm Sci."},{"key":"B137","first-page":"597","article-title":"Glycine and n-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications","volume":"50","author":"Danysz","year":"1998","journal-title":"Pharmacol Rev"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2016.3955","article-title":"D-cycloserine augmentation of exposure-based cognitive behavior therapy for anxiety, obsessive-compulsive, and posttraumatic stress disorders a systematic review and meta-analysis of individual participant data","author":"Mataix-Cols","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"B139","doi-asserted-by":"publisher","first-page":"e0173660","DOI":"10.1371\/journal.pone.0173660","article-title":"D-cycloserine augmentation of behavior therapy for anxiety and obsessive-compulsive disorders: a meta-analysis","volume":"12","author":"B\u00fcrkner","year":"2017","journal-title":"PLoS ONE."},{"key":"B140","doi-asserted-by":"publisher","first-page":"e0223729","DOI":"10.1371\/journal.pone.0223729","article-title":"Effect of d-cycloserine on fear extinction training in adults with social anxiety disorder","volume":"14","author":"Hofmann","year":"2019","journal-title":"PLoS ONE."},{"key":"B141","doi-asserted-by":"publisher","first-page":"131S","DOI":"10.1016\/0002-9343(91)90296-a","article-title":"Use of n-acetylcysteine in clinical toxicology","volume":"91","author":"Flanagan","year":"1991","journal-title":"Am J Med"},{"key":"B142","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2147\/copd.2006.1.2.99","article-title":"The role for n-acetylcysteine in the management of cOPD","volume":"1","author":"Dekhuijzen","year":"2006","journal-title":"Int J Chron Obstruct Pulm Dis"},{"key":"B143","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/ajad.12620","article-title":"N-acetylcysteine in the treatment of craving in substance use disorders: Systematic review and meta-analysis","volume":"26","author":"Duailibi","year":"2017","journal-title":"Am J Addict"},{"key":"B144","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1080\/14734220601142878","article-title":"N-acetylcysteine and neurodegenerative diseases: basic and clinical pharmacology","volume":"6","author":"Arakawa","year":"2007","journal-title":"Cerebellum."},{"key":"B145","first-page":"190","article-title":"Placebo-controlled augmentation trials of the antioxidant NAC in schizophrenia: a review","volume":"28","author":"Chen","year":"2016","journal-title":"Ann Clin Psychiatry."},{"key":"B146","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1161\/STROKEAHA.118.021755","article-title":"Protective effects of brain infarction by n-Acetylcysteine derivatives","volume":"49","author":"Uemura","year":"2018","journal-title":"Stroke."},{"key":"B147","doi-asserted-by":"publisher","first-page":"716458","DOI":"10.1155\/2008\/716458","article-title":"Inhibitory effect on cerebral inflammatory response following traumatic brain injury in rats: a potential neuroprotective mechanism of n-Acetylcysteine","volume":"2008","author":"Chen","year":"2008","journal-title":"Med Inflamm"},{"key":"B148","doi-asserted-by":"publisher","first-page":"12","DOI":"10.9758\/cpn.2015.13.1.12","article-title":"N-acetyl cysteine in the treatment of obsessive compulsive and related disorders: a systematic review","volume":"13","author":"Oliver","year":"2015","journal-title":"Clin Psychopharmacol Neurosci."},{"key":"B149","doi-asserted-by":"publisher","first-page":"457","DOI":"10.4088\/JCP.15r09984","article-title":"N-acetylcysteine in depressive symptoms and functionality: A systematic review and meta-analysis","volume":"77","author":"Fernandes","year":"2016","journal-title":"J Clin Psychiatry"},{"key":"B150","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.neubiorev.2015.04.015","article-title":"Clinical trials of N-acetylcysteine in psychiatry and neurology: a systematic review","volume":"55","author":"Deepmala Slattery","year":"2015","journal-title":"Neurosci Biobehav Rev."},{"key":"B151","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.pmrj.2009.10.010","article-title":"Pharmacokinetics of amantadine in children with impaired consciousness due to acquired brain injury: preliminary findings using a sparse-sampling technique","volume":"2","author":"Vargus-Adams","year":"2010","journal-title":"PM&R"},{"key":"B152","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1089\/cap.2012.0066","article-title":"Treatment with adjunctive n-acetylcysteine in an adolescent with selective serotonin reuptake inhibitor-resistant anxiety","volume":"22","author":"Strawn","year":"2012","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"B153","doi-asserted-by":"publisher","first-page":"e766","DOI":"10.4088\/JCP.16m11101","article-title":"Randomized, double-blind, placebo-controlled trial of n-acetylcysteine augmentation for treatment-resistant obsessive-compulsive disorder","volume":"78","author":"Costa","year":"2017","journal-title":"J Clin Psychiatry."},{"key":"B154","doi-asserted-by":"publisher","first-page":"628","DOI":"10.4088\/jcp.13m08454","article-title":"The efficacy of adjunctive n -Acetylcysteine in major depressive disorder","volume":"75","author":"Bush","year":"2014","journal-title":"J Clin Psychiatry."},{"key":"B155","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1001\/archgenpsychiatry.2009.60","article-title":"N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study","volume":"66","author":"Grant","year":"2009","journal-title":"Arch Gen Psychiatry."},{"key":"B156","doi-asserted-by":"publisher","first-page":"761","DOI":"10.2165\/00023210-200822090-00004","article-title":"Riluzole in the treatment of mood and anxiety disorders","volume":"22","author":"Pittenger","year":"2008","journal-title":"CNS Drugs"},{"key":"B157","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.psychres.2019.06.020","article-title":"Efficacy and tolerability of riluzole in psychiatric disorders: a systematic review and preliminary meta-analysis","volume":"278","author":"De Boer","year":"2019","journal-title":"Psychiatry Res"},{"key":"B158","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.4088\/JCP.14m09123","article-title":"Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial","volume":"76","author":"Pittenger","year":"2015","journal-title":"J Clin Psychiatry."},{"key":"B159","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neuropharm.2011.08.040","article-title":"The gABA system in anxiety and depression and its therapeutic potential","volume":"62","author":"M\u00f6hler","year":"2012","journal-title":"Neuropharmacol."},{"key":"B160","first-page":"21","article-title":"The role of GABA in anxiety disorders","volume":"64","author":"Lydiard","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"B161","doi-asserted-by":"publisher","first-page":"4943","DOI":"10.2174\/1381612821666150914121624","article-title":"GABA receptors: pharmacological potential and pitfalls","volume":"21","author":"Jembrek","year":"2015","journal-title":"Curr Pharm Design."},{"key":"B162","doi-asserted-by":"publisher","first-page":"2064027","DOI":"10.1155\/2018\/2064027","article-title":"Mechanisms underlying aggressive behavior induced by antiepileptic drugs: focus on topiramate, levetiracetam, and perampanel","volume":"2018","author":"Hansen","year":"2018","journal-title":"Behav Neurol"},{"key":"B163","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1080\/00952990802308213","article-title":"Levetiracetam for the treatment of co-occurring alcohol dependence and anxiety: case series and review","volume":"34","author":"Mariani","year":"2008","journal-title":"Am J Drug Alcohol Abuse."},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.446","article-title":"Gabapentin and pregabalin for the treatment of anxiety disorders","author":"Greenblatt","year":"2018","journal-title":"Clin Pharm Drug Dev"},{"key":"B165","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1177\/0269881115598411","article-title":"Efficacy and safety of pregabalin in generalised anxiety disorder: a critical review of the literature","volume":"29","author":"Baldwin","year":"2015","journal-title":"J Psychopharmacol."},{"key":"B166","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/YIC.0000000000000147","article-title":"Pregabalin for generalized anxiety disorder: an updated systematic review and meta-analysis","volume":"32","author":"Generoso","year":"2017","journal-title":"Int Clin Psychopharmacol"},{"key":"B167","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1097\/YIC.0b013e328350b133","article-title":"Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to sSRI or sNRI treatment","volume":"27","author":"Rickels","year":"2012","journal-title":"Int Clin Psychopharmacol."},{"key":"B168","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1517\/14656566.2.1.179","article-title":"Pharmacology and clinical experience with tiagabine","volume":"2","author":"Schachter","year":"2001","journal-title":"Exp Opin Pharmacother."},{"key":"B169","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/hup.846","article-title":"Tiagabine for social anxiety disorder","volume":"22","author":"Dunlop","year":"2007","journal-title":"Hum Psychopharmacol."},{"key":"B170","first-page":"32","article-title":"An open-label study of tiagabine in panic disorder","volume":"40","author":"Sheehan","year":"2007","journal-title":"Psychopharmacol Bull."},{"key":"B171","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1055\/s-0029-1241798","article-title":"Effects of the gABA-reuptake inhibitor tiagabine on panic and anxiety in patients with panic disorder","volume":"42","author":"Zwanzger","year":"2009","journal-title":"Pharmacopsychiatry."},{"key":"B172","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/10401230591002138","article-title":"An open-label study of tiagabine as augmentation therapy for anxiety","volume":"17","author":"Schwartz","year":"2005","journal-title":"Ann Clin Psychiatry."},{"key":"B173","doi-asserted-by":"publisher","first-page":"752","DOI":"10.2165\/00003495-199754050-00009","article-title":"Topiramate. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy","volume":"54","author":"Langtry","year":"1997","journal-title":"Drugs"},{"key":"B174","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.4088\/JCP.v65n1213","article-title":"An open trial of topiramate in the treatment of generalized social phobia","volume":"65","author":"Van Ameringen","year":"2004","journal-title":"J Clin Psychiatry."},{"key":"B175","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/FPC.0b013e32835ea0b2","article-title":"Valproic acid pathway: pharmacokinetics and pharmacodynamics","volume":"23","author":"Ghodke-Puranik","year":"2013","journal-title":"Pharm Genom."},{"key":"B176","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1177\/070674379003500309","article-title":"Valproic acid and panic disorder","volume":"35","author":"Primeau","year":"1990","journal-title":"Can J Psychiatry."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2020.548505\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T04:46:40Z","timestamp":1605761200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2020.548505\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,19]]},"references-count":176,"alternative-id":["10.3389\/fpsyt.2020.548505"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2020.548505","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,19]]},"article-number":"548505"}}